Epicrispr reports encouraging early data from EPI-321 in 12 patients with FSHD
read at Endpoints ↗Positive readoutPositive
Epicrispr Biotechnologies released updated data on its epigenetic editing therapy EPI-321 aimed at treating facioscapulohumeral muscular dystrophy (FSHD).
The company has now dosed twelve participants with the investigational product, and the latest results indicate a favorable safety profile and early signals of biological activity.
These findings strengthen the company's case for advancing EPI-321 in the development program and suggest the approach could address the underlying genetic cause of FSHD, though further studies are needed.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Epicrispr builds case for FSHD treatment with updated data for EPI-321”
read at Endpoints ↗91 words · retrieved 57m ago
comments(0)
5-min edit window · permanent after that